OncLive TV

Dr. Bauml on KEYNOTE-055 Study for Patients With HNSCC

June 30th 2016

Joshua M. Bauml, MD, assistant professor of Medicine, Hospital of the University of Pennsylvania and the Veteran's Administration Medical Center, discusses the preliminary results of the KEYNOTE-055 study, which investigated pembrolizumab (Keytruda) after failure on platinum-based therapy and cetuximab in patients with head and neck squamous cell carcinoma.

Dr. Yurgelun on Susceptibility Gene Mutations in CRC

June 30th 2016

Dr. Mateos on Ixazomib-Lenalidomide-Dexamethasone in Relapsed/Refractory Multiple Myeloma

June 30th 2016

Dr. Chagpar on Surgical Treatment of Patients With HER2+ Breast Cancer

June 29th 2016

Anees B. Chagpar, MD, associate professor of Surgery (Oncology) and director of The Breast Center at Smilow Cancer Hospital at Yale-New Haven, discusses how surgical oncologists should approach the treatment of a patient with HER2-positive breast cancer.

Dr. Spigel on CheckMate-331 Trial for SCLC

June 29th 2016

David Spigel, MD, chief scientific officer, director, Lung Cancer Research Program, principal investigator, Sarah Cannon Research Institute, discusses the ongoing CheckMate-331 trial, which is investigating nivolumab (Opdivo) versus chemotherapy in relapsed patients with small cell lung cancer (SCLC) after first-line platinum-based chemotherapy.

Dr. Marc Bjurlin on Predictive Models for Prostate Cancer Risk

June 29th 2016

Dr. Stacy Loeb on Screening Considerations in Prostate Cancer

June 28th 2016

Dr. Hughes on RT in Elderly Patients With ER+ Breast Cancer

June 28th 2016

Kevin S. Hughes, MD, co-director, Avon Comprehensive Breast Evaluation Center, medical director, Bermuda Cancer Genetics and Risk Assessment Clinic, Harvard Medical School, Massachusetts General Hospital, discusses treatment with radiation therapy for patients with ER-positive breast cancer.

The Impact of Lymphedema in Patients With Head and Neck Cancer

June 28th 2016

Jan S. Lewin, PhD, professor, Department of Head and Neck Surgery, Division of Surgery, The University of Texas MD Anderson Cancer Center, discusses the impact of lymphedema in patients with head and neck cancer.

Dr. Gary Steinberg on New AUA Guidelines for Bladder Cancer

June 28th 2016

Dr. Muss on Assessing Treatment Response in Patients With Metastatic Breast Cancer

June 27th 2016

Hyman B. Muss, MD, School of Medicine, University of North Carolina (UNC)-Chapel Hill, Breast Cancer, Geriatric Oncology Program, Mary Jones Hudson Distinguished Professorship in Geriatric Oncology, discusses assessing treatment response in patients with metastatic breast cancer.

Dr. Andtbacka on Optimal Use of T-VEC in Melanoma

June 27th 2016

Robert Andtbacka, MD, associate professor in the Division of Surgical Oncology, Department of Surgery at the University of Utah School of Medicine, discusses the optimal use of talimogene laherparepvec (T-VEC) in patients with melanoma.

Dr. Raghav on HER2 Amplification in Patients With CRC

June 24th 2016

Kanwal Raghav, MBBS, MD, assistant professor, Department of Gastrointestinal Medical Oncology, Division of Cancer Medicine, The University of Texas MD Anderson Cancer Center, discusses a study examining HER2 gene amplification in patients with metastatic colorectal cancer.

Dr. Charles Ryan Discusses IMAAGEN Trial Update for Prostate Cancer

June 23rd 2016

Charles J. Ryan, MD, professor of Clinical Medicine, Urology, Helen Diller Family Comprehensive Cancer Center at the University of California, San Francisco, provides an update to the IMAAGEN trial, which explored the effects of abiraterone acetate (Zytiga) and low-dose prednisone on prostate-specific antigen and radiographic disease progression in patients with nonmetastatic castration-resistant prostate cancer

Dr. Jorge Sierra on Risk Adapted Therapy in AML

June 23rd 2016

Dr. Wolchok on Updated CheckMate-067 Results for Melanoma

June 22nd 2016

Jedd D. Wolchok, MD, PhD, chief, Melanoma and Immunotherapeutics Service, Department of Medicine and Ludwig Center at Memorial Sloan Kettering Cancer Center, discusses the updated findings from the CheckMate-067 trial, which explored nivolumab (Opdivo) combined with ipilimumab (Yervoy) in treatment-naive patients with advanced melanoma.

Dr. Mehra on KEYNOTE-012 Results of Pembrolizumab in Head and Neck Cancer

June 22nd 2016

Ranee Mehra, MD, chief, Head and Neck Hematology/Oncology, associate professor, Department of Hematology/Oncology, Fox Chase Cancer Center, discusses the results of the KEYNOTE-012 study, which examined the efficacy of pembrolizumab (Keytruda) in patients with recurrent/metastatic head and neck squamous cell carcinoma.

Dr. Sartor on Mechanism of Action and Safety of Radium-223 in mCRPC

June 21st 2016

Oliver Sartor, MD, medical director of Tulane Cancer Center, discusses the mechanism of action of radium-223 dichloride (Xofigo) as well as its safety profile for the treatment of patients with metastatic castration-resistant prostate cancer (mCRPC).

Dr. John Byrd on Challenges in CLL

June 21st 2016

Dr. Yardley on HERMIONE-2 Trial for HER2+ Breast Cancer

June 20th 2016

Denise A. Yardley, MD, senior investigator, Breast Cancer Research Program, principal investigator, Sarah Cannon Research Institute, discusses the phase II HERMIONE-2 trial, which is a randomized, open label trial comparing MM-302 plus trastuzumab with chemotherapy of physician’s choice plus trastuzumab, in patients with anthracycline-naive HER2-positive, locally advanced/metastatic breast cancer who were previously treated with pertuzumab and ado-trastuzumab emtansine (T-DM1).